🔎 Trials Near Me

Beranda › Penyakit Crohn › Indiana

Uji klinis Penyakit Crohn di Indiana

13 studi untuk Penyakit Crohn mencari peserta di lokasi di Indiana.

Kota di Indiana

Teks studi resmi (Bahasa Inggris)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Indiana University Health University Hospital ( Site 5022), Indianapolis
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastroenterology Health Partners /ID# 284145, New Albany
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07697456

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Indiana University Health University Hospital /ID# 278129, Indianapolis
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • IU Health University Hospital, Indianapolis
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07196722

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Riley Hospital for Children, Indianapolis
Menerima pesertaFase 3
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06663332

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Indiana University Health University Hospital, Indianapolis
  • Gastroenterology Health Partners, New Albany
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05995353

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Riley Childrens Hospital, Indianapolis
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05509777

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Riley Hospital for Children at Indiana University Health, Indianapolis
Menerima pesertaFase 4
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT05781152

Precise Infliximab Exposure and Pharmacodynamic Control

  • Riley Hospital for Children, Indianapolis
Menerima pesertaFase 2/3
Usia 6 hingga 22 · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT05660746

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.